Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. / Iversen, P; Suciu, S; Sylvester, R; Christensen, I; Denis, L.

I: Cancer, Bind 66, Nr. 5 Suppl, 1990, s. 1067-73.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Iversen, P, Suciu, S, Sylvester, R, Christensen, I & Denis, L 1990, 'Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86', Cancer, bind 66, nr. 5 Suppl, s. 1067-73.

APA

Iversen, P., Suciu, S., Sylvester, R., Christensen, I., & Denis, L. (1990). Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer, 66(5 Suppl), 1067-73.

Vancouver

Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer. 1990;66(5 Suppl):1067-73.

Author

Iversen, P ; Suciu, S ; Sylvester, R ; Christensen, I ; Denis, L. / Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. I: Cancer. 1990 ; Bind 66, Nr. 5 Suppl. s. 1067-73.

Bibtex

@article{b8d2a859571241caad1b58039c657b4a,
title = "Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86",
abstract = "A total of 591 patients with advanced prostatic cancer have been randomized to either orchiectomy or treatment with zoladex 3.6 mg as a depot preparation combined with flutamide 250 mg tid in two European studies, EORTC protocol 30853 and DAPROCA 86. Identical design and comparable patient characteristics in the two studies have allowed combined analysis. A small but statistically significant difference in time to objective progression or death from prostatic cancer was found in favor of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchiectomy. Thus, no difference between treatment groups in overall survival was found. As a conclusion, the combined androgen blockade was not superior to orchiectomy in the treatment of patients with advanced prostatic cancer.",
author = "P Iversen and S Suciu and R Sylvester and I Christensen and L Denis",
year = "1990",
language = "English",
volume = "66",
pages = "1067--73",
journal = "Cancer",
issn = "0008-543X",
publisher = "JohnWiley & Sons, Inc.",
number = "5 Suppl",

}

RIS

TY - JOUR

T1 - Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86

AU - Iversen, P

AU - Suciu, S

AU - Sylvester, R

AU - Christensen, I

AU - Denis, L

PY - 1990

Y1 - 1990

N2 - A total of 591 patients with advanced prostatic cancer have been randomized to either orchiectomy or treatment with zoladex 3.6 mg as a depot preparation combined with flutamide 250 mg tid in two European studies, EORTC protocol 30853 and DAPROCA 86. Identical design and comparable patient characteristics in the two studies have allowed combined analysis. A small but statistically significant difference in time to objective progression or death from prostatic cancer was found in favor of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchiectomy. Thus, no difference between treatment groups in overall survival was found. As a conclusion, the combined androgen blockade was not superior to orchiectomy in the treatment of patients with advanced prostatic cancer.

AB - A total of 591 patients with advanced prostatic cancer have been randomized to either orchiectomy or treatment with zoladex 3.6 mg as a depot preparation combined with flutamide 250 mg tid in two European studies, EORTC protocol 30853 and DAPROCA 86. Identical design and comparable patient characteristics in the two studies have allowed combined analysis. A small but statistically significant difference in time to objective progression or death from prostatic cancer was found in favor of the combination treatment. However, time from objective progression to death was longer in the group initially allocated to orchiectomy. Thus, no difference between treatment groups in overall survival was found. As a conclusion, the combined androgen blockade was not superior to orchiectomy in the treatment of patients with advanced prostatic cancer.

M3 - Journal article

VL - 66

SP - 1067

EP - 1073

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5 Suppl

ER -

ID: 48470223